agenmestencel-T (MSC_APCETH_101)
/ Minaris Regenerative Medicine
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
May 19, 2019
Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: Final results of the phase 1/2 TREAT-ME-1 trial.
(ASCO 2019)
- P1/2; "MSC_apceth_101 in combination with ganciclovir was safe and tolerable in patients with advanced gastrointestinal adenocarcinoma, with preliminary signs of efficacy in terms of clinical stabilization of disease. Clinical trial information: NCT02008539"
Clinical • P1/2 data
February 26, 2019
Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: results from the Phase 1/2 TREAT-ME-1 Trial.
(PubMed, Int J Cancer)
- "No clear trends in the immunological markers assessed were observed. MSC_apceth_101 in combination with ganciclovir was safe and tolerable in patients with advanced gastrointestinal adenocarcinoma, with preliminary signs of efficacy in terms of clinical stabilization of disease."
Journal • P1/2 data
1 to 2
Of
2
Go to page
1